Medical Device Network on MSN
Adagio Medical seeks FDA PMA for ventricular ablation system
The application draws on data from the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients across 20 centres.
Adagio Medical (Nasdaq:ADGM) announced today that it submitted its premarket approval (PMA) application to the FDA for its ...
April 30, 2004 — An infusion of n-3 polyunsaturated fatty acids (PUFA) had immediate inhibitory effects on sustained ventricular tachycardia, according to the results of a pilot study published in the ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with ventricular tachycardia indicated for an implantable cardioverter ...
Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results